HCA

Business profile & competitive position

HCA Healthcare, Inc. sits in the Healthcare sector under the Medical - Care Facilities industry. As of December 31, 2025, the company operated 190 hospitals—179 general acute care, seven behavioral, and four rehabilitation facilities—plus 121 freestanding ambulatory surgery centers and 31 freestanding endoscopy centers across 19 U.S. states and England. Its service mix spans inpatient and outpatient medical/surgical care, emergency and diagnostic services, mental health, and ancillary services delivered through ASCs, urgent/walk-in clinics, physician practices, home health agencies, hospices, and rehabilitation facilities.

The scale is significant: 179 general acute care hospitals alone hold 50,436 licensed beds, with behavioral hospitals adding another 714 beds. For 2025, HCA reported $75.6 billion in revenue, with 48.9% coming from managed care and other insurers and 14.9% from Medicare. That payer mix tells investors that HCA’s top line is driven more by commercial insurance pricing than by direct government reimbursement, though Medicare still matters.

On the profitability side, the 8.8% net margin suggests the company converts a meaningful share of revenue into bottom-line income, which is consistent with the cost advantages that large hospital operators can extract from scale, purchasing, and fixed-cost absorption. However, the ROE of -112.9% is deeply negative. A negative ROE usually signals that shareholders’ equity is negative on the balance sheet—often the result of accumulated share buybacks, dividends, and accounting adjustments rather than an operating loss. Because the data shows a positive net margin but a negative book equity base, the margin looks healthy while the equity-return metric is mathematically distorted. That combination does not, by itself, prove a wide competitive moat, but it does show a capital structure where debt and shareholder distributions have substantially outweighed retained earnings.

Financial posture

HCA currently carries a market capitalization of $92.4 billion and trades at a trailing P/E of 14.3. That multiple sits below the level many growth-oriented healthcare names command, which is consistent with HCA’s identity as a mature, capital-intensive facility operator rather than a high-growth biotech or device name. The company’s beta is 1.11, implying slightly more market sensitivity than the average stock.

The 8.8% net margin is the cleaner measure of earnings power here, because the -112.9% ROE is being driven by a thin or negative equity base rather than by poor operations. Investors looking at HCA need to focus on cash-flow generation, debt-service capacity, and the sustainability of that margin, since traditional return-on-equity framing is not useful when book equity is negative. Without a debt figure in the current snapshot, the key takeaway is that HCA’s valuation looks moderate on earnings but its balance-sheet structure makes simple ROE-based comparisons misleading.

Strategic priorities & outlook

HCA’s most recent 10-K filing outlines four operational priorities. First, the company intends to grow its presence in existing markets, suggesting that capital deployment will focus on deepening share in geographies it already knows rather than broad geographic expansion. Second, it aims to achieve industry-leading performance in clinical, operational, and satisfaction measures, which matters in a reimbursement environment where quality scores and patient experience can affect volumes and contract terms. Third, HCA emphasizes recruiting and retaining physicians and other health care professionals to meet demand for high-quality services—an important priority given national shortages of nurses and clinicians. Fourth, the company plans to advance its digital and artificial-intelligence capabilities, which could eventually show up in scheduling, clinical decision support, revenue-cycle efficiency, and labor allocation.

Operationally, the filing also highlights a heavy concentration in Florida and Texas. Because a meaningful portion of HCA’s beds and facilities are in those two states, local regulatory, economic, public-health, and competitive conditions there can have an outsize effect on results.

Macro & geopolitical exposure

As a Medical - Care Facilities operator, HCA is exposed to the structural forces that shape U.S. healthcare. Reimbursement risk is central: Medicare, Medicaid, and managed-care contract rates all influence revenue per admission and per procedure. Changes to federal healthcare legislation, state Medicaid expansion decisions, or CMS payment rules can quickly affect profitability. Medical malpractice and tort reform also matter for hospital operators, as do state-level certificate-of-need laws that restrict new facility construction.

Labor is another macro exposure. Hospitals rely on physicians, nurses, technicians, and support staff, so wage inflation, union activity, and clinical labor shortages flow directly into margins. Supply-chain costs for pharmaceuticals and medical devices can move with commodity prices, freight rates, and trade policy, although HCA’s domestic footprint means currency exposure is minimal outside its small England presence. Finally, geographic concentration in Florida and Texas adds state-specific risks, including hurricane-related disruption, local economic cycles, and divergent state Medicaid policies.

Recent developments

On September 17, 2026, MarketBeat reported that “HCA Healthcare Sees Solid Demand as Exchange Headwinds Pressure 2026 Outlook.” That headline captures the current operating tension: underlying patient demand appears firm, but exchange-plan profitability or pricing is creating pressure on the 2026 outlook.

The same day, PR Newswire carried a note that Pomerantz Law Firm is investigating claims on behalf of HCA investors. None of the allegations are specified in the available headline, so it is best treated as headline litigation risk rather than a quantified liability. Also on September 17, Defense World reported that Bank of America Corp DE made a new investment in HCA—a data point showing continued institutional attention despite the exchange-plan concerns.

One day earlier, on September 16, 2026, Seeking Alpha published the transcript of HCA’s presentation at the 2026 Jefferies Healthcare Services and Technology Conference. That kind of conference appearance typically gives investors insight into management’s current volume, pricing, labor, and capital-allocation messaging.

Earnings behavior & post-earnings drift

HCA has delivered an earnings beat in each of the last eight reported quarters, for a 100% beat rate, with an average earnings surprise of 6.4%. Over that same span, the average 5-day price move after earnings was +1.75%, classified as an “up” drift. That suggests that, on average, the stock continues to adjust higher in the days following the earnings release.

The most recent quarter, reported on July 24, 2026, showed EPS of $7.59 versus an estimate of $7.56—only a 0.4% surprise—but the stock rose 1.94% the next day and 5.34% over the following five days. In the prior quarter, April 24, 2026, HCA earned $7.15 vs. $7.12 estimated, also a 0.4% beat, and the next-day move was +3.09%, though the five-day drift was just +0.15%.

By contrast, the January 27, 2026 quarter produced a much larger 7.4% beat—$8.01 actual vs. $7.46 estimate—but the stock fell 2.89% the next day and 1.31% over the following five days. That reaction is a useful reminder that beating estimates does not guarantee a positive price response, especially when expectations or guidance color the read-through. The October 24, 2025 quarter was the largest beat of the four, with actual EPS of $6.96 vs. $5.79 estimated (a 20.2% surprise), driving a 4.66% next-day gain and a 2.83% five-day gain.

HCA is scheduled to report next on October 23, 2026, before the open, with a consensus EPS estimate of $6.70. As of the latest snapshot, the stock trades at $426.93, with an RSI of 57.6 and a 50-day EMA of $413.07.